Precision oncology may look elegantly targeted from the outside, but delivering it inside a clinical trial requires coordination across testing, data, timing, sites, patients, and specialized teams.

“Prior lines of therapy” looks simple in an eligibility criterion until real patient histories are involved. What counts as a line can change eligibility, interpretation, and ultimately who enters the trial.

A CTCAE grade gives a toxicity a standardized label, but it cannot capture the full clinical story. Timing, trajectory, reversibility, context, and patient impact can matter just as much as the number.

Oncology trials rarely unfold without obstacles. The real work is not avoiding every challenge, but recognizing what matters, understanding the context, and making thoughtful decisions when the study gets complicated.

A dose-limiting toxicity is more than a protocol checkbox. DLT adjudication requires clinical context, pattern recognition, and judgment because one decision can shape the direction of an entire development program.